Insilico Medicine receives FDA clearance for AI-designed cancer drug ISM5939

Insilico Medicine has received FDA clearance for ISM5939, an AI-designed drug aimed at treating solid tumors. This marks the company's tenth AI-driven molecule to enter clinical trials, highlighting its advancements in drug discovery. ISM5939 targets ENPP1, a protein linked to cancer progression. Preclinical studies showed it has strong anti-tumor effects and a favorable safety profile, suggesting potential for use in cancer immunotherapy. Insilico's AI platform has led to the nomination of 20 preclinical candidates since 2021, with 10 receiving IND approvals. The company continues to focus on integrating AI in drug development to enhance treatment options for patients.